Nanobiotix S.A. (NBTX) financials: revenue, earnings and cash flow
Fiscal 2018–2025 · from SEC filings · data as of November 13, 2026
Summary
Nanobiotix’s revenue went from $4M in fiscal 2018 to $38M in fiscal 2025, growth of about 38.2% a year.
Net income in fiscal 2025 was -$28M, a net margin of -73.5%; the highest of the period.
Free cash flow was -$40M in fiscal 2025 and positive in 0 of the 8 years shown.
Revenue, profit and cash flow by year
Income statement
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $38M | -$7M | $40M | $5M | $3M | $3M | $3M | $4M |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$13M | -$71M | -$30M | -$50M | -$60M | -$45M | -$53M | -$34M |
| Net income | -$28M | -$71M | -$44M | -$61M | -$53M | -$41M | -$57M | -$35M |
| EPS (diluted) | $-0.55 | $-1.39 | $-0.86 | $-1.20 | $-1.05 | $-0.81 | $-1.13 | $-0.68 |
| R&D | — | — | — | — | — | — | — | — |
| Revenue growth | +612.6% | −118.7% | +685.4% | +69.9% | −2.7% | +8.0% | −28.3% | — |
Cash flow
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$39M | -$20M | -$14M | -$40M | -$34M | -$34M | -$46M | -$30M |
| Capital spending | -$632153 | -$878906 | -$362439 | -$98127 | -$258234 | -$117802 | -$1M | -$476321 |
| Free cash flow | -$40M | -$21M | -$14M | -$40M | -$34M | -$34M | -$47M | -$30M |
| Dividends paid | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Buybacks | — | — | — | — | — | — | — | — |
| Stock-based pay | $4M | $4M | $4M | $3M | $4M | $4M | $5M | $2M |
Balance sheet
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|
| Cash | $62M | $52M | $83M | $44M | $95M | $146M | $39M | $41M |
| Debt | $0 | $0 | $0 | $0 | $0 | $0 | — | — |
| Equity | -$99M | -$68M | -$2M | -$29M | $30M | $86M | -$2M | $16M |
| Total assets | $80M | $70M | $104M | $64M | $115M | $164M | $63M | $59M |
| Shares (diluted) | 51M | 51M | 51M | 51M | 51M | 51M | 51M | 51M |
Margins and returns
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | -33.2% | 951.1% | -74.0% | -977.8% | -1986.4% | -1450.2% | -1841.0% | -864.2% |
| Net margin | -73.5% | 947.5% | -109.7% | -1194.3% | -1778.0% | -1337.2% | -2003.7% | -872.2% |
| FCF margin | -104.2% | 283.6% | -35.4% | -778.8% | -1137.1% | -1100.1% | -1663.1% | -758.9% |
| ROIC | — | — | — | — | -155.1% | -40.8% | — | -211.1% |
| ROE | 28.4% | 103.7% | 2154.1% | 210.9% | -175.7% | -47.7% | 2668.5% | -213.1% |
Frequently asked questions
What is Nanobiotix’s annual revenue?
$38M in fiscal 2025.
How much profit does Nanobiotix make?
Net income was -$28M in fiscal 2025 (net margin -73.5%).
Is Nanobiotix’s revenue growing?
No: revenue fell 612.6% in fiscal 2025 compared with the year before.
From the company’s 10-K and 10-Q filings with the SEC; per-share figures adjusted for stock splits. Rebuilt daily. Not investment advice.